Fiche publication
Date publication
juillet 2026
Journal
Nature communications
Auteurs
Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria
Tous les auteurs :
Garbe C, Keim U, Amaral T, Ascierto PA, Bauer J, Dummer R, Eggermont AMM, Eigentler TK, Flatz L, Forchhammer S, Forschner A, Gandini S, Gershenwald JE, Hauschild A, Hoeller C, Kirkwood JM, Lebbe C, Long GV, Lorigan P, Luke JJ, Meier F, Metzler G, Nathan P, Postow MA, Robert C, Röcken M, Schadendorf D, Weide B, Whiteman D, Leiter U, Martus P
Lien Pubmed
Résumé
A false-negative diagnosis of cancer can lead to a delay in effective treatment and a poorer prognosis. Here, we use the example of cutaneous melanoma to examine how many years of life are lost after a false-negative diagnosis compared to a primarily correct diagnosis. From 1996 to 2015, 9,063 patients are prospectively registered in the German Central Malignant Melanoma Registry and followed up until December 2023. A false-negative diagnosis is found in 206 (2.3%) patients. The median time to correct diagnosis is 24.0 months. The 10-year recurrence-free survival probabilities are 32.9% for false-negative diagnoses and 76.2% for correct diagnoses (p < 0.001). The 10-year melanoma-specific survival probabilities are 62.1% versus 85.0% (p < 0.001). On average, each person with an initial false-negative diagnosis loses 8.2 years of life compared to people with a correct diagnosis. This high number of years of life lost raises the question of whether similar results also apply to other types of cancer.
Mots clés
Humans, Melanoma, diagnosis, Germany, epidemiology, Registries, Female, Prospective Studies, Male, False Negative Reactions, Skin Neoplasms, diagnosis, Aged, Middle Aged, Aged, 80 and over, Cutaneous Malignant Melanoma, Adult, Prognosis, Life Expectancy
Référence
Nat Commun. 2026 07 2;17(1):
